Drug-Resistant Aspergillus spp.: A Literature Review of Its Resistance Mechanisms and Its Prevalence in Europe
- PMID: 38003770
- PMCID: PMC10674884
- DOI: 10.3390/pathogens12111305
Drug-Resistant Aspergillus spp.: A Literature Review of Its Resistance Mechanisms and Its Prevalence in Europe
Abstract
Infections due to the Aspergillus species constitute an important challenge for human health. Invasive aspergillosis represents a life-threatening disease, mostly in patients with immune defects. Drugs used for fungal infections comprise amphotericin B, triazoles, and echinocandins. However, in the last decade, an increased emergence of azole-resistant Aspergillus strains has been reported, principally belonging to Aspergillus fumigatus species. Therefore, both the early diagnosis of aspergillosis and its epidemiological surveillance are very important to establish the correct antifungal therapy and to ensure a successful patient outcome. In this paper, a literature review is performed to analyze the prevalence of Aspergillus antifungal resistance in European countries. Amphotericin B resistance is observed in 2.6% and 10.8% of Aspergillus fumigatus isolates in Denmark and Greece, respectively. A prevalence of 84% of amphotericin B-resistant Aspergillus flavus isolates is reported in France, followed by 49.4%, 35.1%, 21.7%, and 20% in Spain, Portugal, Greece, and amphotericin B resistance of Aspergillus niger isolates is observed in Greece and Belgium with a prevalence of 75% and 12.8%, respectively. The prevalence of triazole resistance of Aspergillus fumigatus isolates, the most studied mold obtained from the included studies, is 0.3% in Austria, 1% in Greece, 1.2% in Switzerland, 2.1% in France, 3.9% in Portugal, 4.9% in Italy, 5.3% in Germany, 6.1% in Denmark, 7.4% in Spain, 8.3% in Belgium, 11% in the Netherlands, and 13.2% in the United Kingdom. The mechanism of resistance is mainly driven by the TR34/L98H mutation. In Europe, no in vivo resistance is reported for echinocandins. Future studies are needed to implement the knowledge on the spread of drug-resistant Aspergillus spp. with the aim of defining optimal treatment strategies.
Keywords: Aspergillus; azole; drug; resistance.
Conflict of interest statement
The author declares no conflict of interest.
Figures






Similar articles
-
Genomic Diversity of Azole-Resistant Aspergillus fumigatus in the United States.mBio. 2021 Aug 31;12(4):e0180321. doi: 10.1128/mBio.01803-21. Epub 2021 Aug 10. mBio. 2021. PMID: 34372699 Free PMC article.
-
Prospective multicenter surveillance of clinically isolated Aspergillus species revealed azole-resistant Aspergillus fumigatus isolates with TR34/L98H mutation in the Kyoto and Shiga regions of Japan.Med Mycol. 2019 Nov 1;57(8):997-1003. doi: 10.1093/mmy/myz003. Med Mycol. 2019. PMID: 30690480
-
Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.Dan Med J. 2016 Oct;63(10):B5288. Dan Med J. 2016. PMID: 27697142 Review.
-
Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia.Front Microbiol. 2015 May 8;6:428. doi: 10.3389/fmicb.2015.00428. eCollection 2015. Front Microbiol. 2015. PMID: 26005442 Free PMC article.
-
Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Mycoses. 2016 Apr;59(4):198-219. doi: 10.1111/myc.12469. Epub 2016 Jan 26. Mycoses. 2016. PMID: 26810669 Review.
Cited by
-
Is neutropenia still the main risk factor for invasive aspergillosis? A contemporary university hospital retrospective cohort of invasive aspergillosis in neutropenic and non-neutropenic patients.Ann Clin Microbiol Antimicrob. 2025 Apr 25;24(1):28. doi: 10.1186/s12941-025-00794-8. Ann Clin Microbiol Antimicrob. 2025. PMID: 40281569 Free PMC article.
-
Antifungal Resistance in Non-fumigatus Aspergillus Species.Mycoses. 2025 Apr;68(4):e70051. doi: 10.1111/myc.70051. Mycoses. 2025. PMID: 40219727 Free PMC article. Review.
-
The Significance of Mono- and Dual-Effective Agents in the Development of New Antifungal Strategies.Chem Biol Drug Des. 2025 Jan;105(1):e70045. doi: 10.1111/cbdd.70045. Chem Biol Drug Des. 2025. PMID: 39841631 Free PMC article. Review.
-
Fungi as an emerging waterborne health concern: impact of treated wastewater discharge versus aerosolization.Environ Sci Process Impacts. 2025 Apr 16;27(4):1103-1119. doi: 10.1039/d5em00020c. Environ Sci Process Impacts. 2025. PMID: 40130584
-
Adaptation Under Pressure: Resistance and Stress Response Interplay in Clinical Aspergillus fumigatus Isolates.J Fungi (Basel). 2025 Jun 2;11(6):428. doi: 10.3390/jof11060428. J Fungi (Basel). 2025. PMID: 40558940 Free PMC article.
References
-
- Babic N., Gunde-Cimerman N., Vargha M., Tischnner Z., Magyar D., Verissimo C., Sabino R., Viegas C., Meyer W., Brandão J. Fungal contaminants in drinlink water regulaton? A tle of ecology, exposure, purification and clinical relevance. Int. J. Environ. Res. Public Health. 2017;14:636. doi: 10.3390/ijerph14060636. - DOI
-
- Warris A., Klaassen C.H.W., Meis J.F.G.M., de Ruiter M.T., de Valk H.A., Abrahamsen T.G., Gaustad P., Verweij P.E. Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J. Clin. Microbiol. 2003;41:4101–4106. doi: 10.1128/JCM.41.9.4101-4106.2003. - DOI - PMC - PubMed
-
- Zanganeh E., Zarrinfar H., Rezaeetalab F., Fata A., Tohidi M., Najafzadeh M.J., Alizadeh M., Seyedmousavi S. Predominance of non-fumigatus Aspergillus species among patients suspectedto pulmonary aspergillosis in a tropical and subtropical region of the MiddleEast. Microb. Pathog. 2018;116:296–300. doi: 10.1016/j.micpath.2018.01.047. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous